This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cummings, E. A. Articles by Rittmaster, R. S. Search for Related Content PubMed PubMed Citation Articles by Cummings, E. A. Articles by Rittmaster, R. S.

Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact?¹

Department of Pediatrics, Division of Endocrinology, IWK Grace Health Centre (E.A.C., S.R.S.); Department of Pathology (M.L.G.); Department of Medicine, Division of Endocrinology (R.S.R.). Dalhousie University, Halifax, Nova Scotia, Canada B3J 3G9

Address all correspondence and requests for reprints to: Sonia R. Salisbury, M.D., Department of Pediatrics, IWK Grace Health Centre, 5850 University Avenue, Halifax, Nova Scotia, Canada, B3J 3G9.

Testolactone, an aromatase inhibitor, blocks conversion of androgens to estrogens. In familial male precocious puberty, slowing of pubertal progression and growth velocity occurs with testolactone and spironolactone. Girls with McCune-Albright syndrome, given testolactone, respond similarly. A 2-yr-old female (case 1) on testolactone for non-McCune-Albright gonadotropin independent precocious puberty had marked elevations of androstenedione (18 ng/mL, normal: 0.2–3.1) and testosterone (3.6 ng/mL, normal < 0.2) but no virilization. Investigations were undertaken to determine whether elevations in testosterone and androstenedione were caused by interference in these RIAs. After a single oral dose of testolactone (5 mg/kg in case 1; 4 mg/kg in case 2, a 3-yr-old boy with familial male precocious puberty; 10 mg/kg in a healthy postmenopausal control), serum testosterone and androstenedione were measured serially by RIA for 24 h. Androstenedione went from normal to a mean peak of 45.4 ng/mL at 1–2 h and returned to baseline by 24 h. Testosterone, undetectable at baseline (case 1 and control) or 1.8 ng/mL (case 2) rose to a mean peak of 6.9 ng/mL and returned to baseline by 24 h. Testolactone, in serial dilutions, cross-reacted in the testosterone assay. Testolactone significantly interferes in these serum RIAs, making their use unreliable in follow-up of patients treated with testolactone.

This article has been cited by other articles:

				L. Soriano-Guillen, N. Lahlou, G. Chauvet, M. Roger, J. L. Chaussain, and J. C. Carel Adult Height after Ketoconazole Treatment in Patients with Familial Male-Limited Precocious Puberty J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 147 - 151. [Abstract] [Full Text] [PDF]

				G. Binder, D. I. Iliev, A. Dufke, M. Wabitsch, R. Schweizer, M. B. Ranke, and M. Schmidt Dominant Transmission of Prepubertal Gynecomastia Due to Serum Estrone Excess: Hormonal, Biochemical, and Genetic Analysis in a Large Kindred J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 484 - 492. [Abstract] [Full Text] [PDF]